Progesterone receptor modulates ERα action in breast cancer
Progesterone receptor modulates ERα action in breast cancer Nature volume 523, pages 313–317 (16 July 2015)
Roles for estrogen and progesterone in breast cancer prevention
Jerry DJ: Roles for estrogen and progesterone in breast cancer prevention. Breast Cancer
Use of different postmenopausal hormone therapies and risk of histology- and hormone receptor-defined invasive breast cancer
Fournier et al J Clin Oncol 26 (8):1260-1268, 2008.
Inadequate corpus luteal function in women with benign breast diseases
Sitruk-Ware et al J Clin Endocrinol Metab 44, 771, 1977.
Endogenous sex hormones and subsequent breast cancer in premenopausal women
Micheli et al Int J Cancer 112, 312-318, 2004.
Percutaneous progesterone use and risk of breast cancer: results from a French cohort study of premenopausal women with benign breast disease
Plu-Bureau G et al Cancer Detect Preve 23(4), 290-296, 1999.
Comparison of regimens containing oral micronized progesterone of medroxyprogesterone acetate on quality of life in postmenopausal women: a cross-sectional survey
Fitzpatrick LA, Pace C, Witta B. Comparison of regimens containing oral micronized progesterone of medroxyprogesterone acetate on quality of life in postmenopausal women: a cross-sectional survey. J Womens Health Gend Based Med. 2000;9(4):381–387.
Comparison of physical and emotional side effects of progesterone or medroxyprogesterone in early postmenopausal women
Cummings JA, Brizendine L. Comparison of physical and emotional side effects of progesterone or medroxyprogesterone in early postmenopausal women. Menopause. 2002;9:253–263.
Menopausal hormone replacement therapy with continuous daily oral mircronized progesterone
Hargrove JT, Maxon WS, Wentz AC, Burnett LS. Menopausal hormone replacement therapy with continuous daily oral mircronized progesterone. Obstet Gynecol. 1989;73(4):606–612.
Effects of progestogens on the postmenopausal breast
de Lignières B. Effects of progestogens on the postmenopausal breast. Climacteric. 2002;5(3):229–235.
Progestins and progesterone in hormone replacement therapy and the risk of breast cancer
Campagnoli C, Clavel-Chapelon F, Kaaks R, Peris C, Berrino F. Progestins and progesterone in hormone replacement therapy and the risk of breast cancer. J Steroid Biochem Mol Biol. 2005;96(2):95–108.
Apoptosis inhibition mediated by medroxyprogesterone acetate treatment of breast cancer cell lines
Ory K, Lebeau J, Levalois C, et al. Apoptosis inhibition mediated by medroxyprogesterone acetate treatment of breast cancer cell lines. Breast Cancer Res Treat. 2001;68(3).
Hormone replacement therapy with estrogen or estrogen plus medroxyprogesterone acetate is associated with increased epithelial proliferation in the normal postmenopausal breast
Hofseth LJ, Raafat AM, Osuch JR, Pathak DR, Slomski CA, Haslam SZ. Hormone replacement therapy with estrogen or estrogen plus medroxyprogesterone acetate is associated with increased epithelial proliferation in the normal postmenopausal breast. J Clin Endocrinol Metab. 1999;84(12):4559–4565.
Estrogenic potential of progestins in oral contraceptives to stimulate human breast cancer cell proliferation
Jeng MH, Parker CJ, Jordan VC. Estrogenic potential of progestins in oral contraceptives to stimulate human breast cancer cell proliferation. Cancer Res. 1992;52(23):6539–6546.
Effects of estradiol with micronized progesterone or medroxyprogesterone acetate on risk markers for breast cancer in postmenopausal monkeys
Wood CE, Register TC, Lees CJ, Chen H, Kimrey S, Cline JM. Effects of estradiol with micronized progesterone or medroxyprogesterone acetate on risk markers for breast cancer in postmenopausal monkeys. Breast Cancer Res Treat. 2007;101(2):125–134.
Effects of progestins on the proliferation of estrogen-dependent human breast cancer cells under growth factor-defined conditions
van der Burg B, Kalkhoven E, Isbrücker L, de Laat SW. Effects of progestins on the proliferation of estrogen-dependent human breast cancer cells under growth factor-defined conditions. J Steroid Biochem Mol Biol. 1992;42(5):457–465.
Influences of percutaneous administration of estradiol and progesterone on human breast epithelial cell cycle in vivo
Chang KJ, Lee TY, Linares-Cruz G, Fournier S, de Ligniéres B. Influences of percutaneous administration of estradiol and progesterone on human breast epithelial cell cycle in vivo. Fertil Steril. 1995;63(4):785–791.
The in vivo effect of the local administration of progesterone on the mitotic activity of human ductal breast tissue
Barrat J, de Lignieres B, Marpeau L, et al. Effect in vivo de l’adminstration locale de progesterone sur l’activite mitotique des glaactorphores humains. [The in vivo effect of the local administration of progesterone on the mitotic activity of human ductal breast tissue. Results of a pilot study.] J Gynecol Obstet Biol Reprod (Paris). 1990;19(3):269–274.
Antiestrogen action of progesterone in breast tissue
Mauvais-Jarvis P, Kuttenn F, Gompel A. Antiestrogen action of progesterone in breast tissue. Breast Cancer Res Treat. 1986;8(3):179– 188.
Progesterone inhibits growth and induces apoptosis in breast cancer cells: inverse effects on Bcl-2 and p53
Formby B, Wiley TS. Progesterone inhibits growth and induces apoptosis in breast cancer cells: inverse effects on Bcl-2 and p53. Ann Clin Lab Sci. 1998;28(6):360–369.
Progesterone inhibits glucocorticoid dependent aromatase induction in human adipose fibroblasts
Schmidt M, Renner C, Löffler G. Progesterone inhibits glucocorticoid dependent aromatase induction in human adipose fibroblasts. J Endocrinol. 1998;158(3):401–407.
The estrogenic activity of synthetic progestins used in oral contraceptives
Jordan VC, Jeng MH, Catherino WH, Parker CJ. The estrogenic activity of synthetic progestins used in oral contraceptives. Cancer. 1993;71(4 suppl):1501–1505.
Pregnancy, progesterone and progestins in relation to breast cancer risk
Campagnoli C, Abba C, Ambroggio S, Peris C. Pregnancy, progesterone and progestins in relation to breast cancer risk. J Steroid Biochem Mol Biol. 2005;97(5):441–450.
Effect of norethisterone acetate on estrogen metabolism in postmenopausal women
Seeger H, Mueck AO, Lippert TH. Effect of norethisterone acetate on estrogen metabolism in postmenopausal women. Horm Metab Res. 2000;32(10):436–439.
Loss of co-ordinate expression of progesterone receptors A and B is an early event in breast carcinogenesis
Mote PA, Bartow S, Tran N, Clarke CL. Loss of co-ordinate expression of progesterone receptors A and B is an early event in breast carcinogenesis. Breast Cancer Res Treat. 2002;72(2):163–172.
Breast cancer risk in relation to different types of hormone replacement therapy in the E3N-EPIC cohort
Fournier A, Berrino F, Riboli E, Avenel V, Clavel-Chapelon F. Breast cancer risk in relation to different types of hormone replacement therapy in the E3N-EPIC cohort. Int J Cancer. 2005;114:448–454.
Unequal risks for breast cancer associated with different hormone replacement therapies: results from the E3N cohort study
Fournier A, Berrino F, Clavel-Chapelon F. Unequal risks for breast cancer associated with different hormone replacement therapies: results from the E3N cohort study. Breast Cancer Res Treat. 2008;107(1):103–111.
Serum hormone levels in pre- menopausal Chinese women in Shanghai and white women in Los Angeles: results from two breast cancer case-control studies
Bernstein L, Yuan JM, Ross RK, et al. Serum hormone levels in pre- menopausal Chinese women in Shanghai and white women in Los Angeles: results from two breast cancer case-control studies. Cancer Causes Control. 1990;1(1):51–58.
Estrogen-progestin replacement therapy and breast cancer risk: the Women’s Health Study (United States)
Porch JV, Lee IM, Cook NR, Rexrode KM, Burin JE. Estrogen-progestin replacement therapy and breast cancer risk: the Women’s Health Study (United States). Cancer Causes Control. 2002;13(9):847–854.
An overview of menopausal oestrogenprogestin hormone therapy and breast cancer risk
Lee SA, Ross RK, Pike MC. An overview of menopausal oestrogenprogestin hormone therapy and breast cancer risk. Br J Cancer. 2005;92(11):2049–2058.
Effect of hormone replacement therapy on breast cancer risk: estrogen versus estrogen plus progestin
Ross RK, Paganini-Hill A, Wan PC, Pike MC. Effect of hormone replacement therapy on breast cancer risk: estrogen versus estrogen plus progestin. J Natl Cancer Inst. 2000;92(4):328–332.
Breast cancer incidence in women with a history of progesterone deficiency
Cowan LD, Gordis L, Tonascia JA, Jones GS. Breast cancer incidence in women with a history of progesterone deficiency. Am J Epidemiol. 1981;114(2):209–217.
Serum progesterone at the time of surgery and survival in women with premenopausal operable breast cancer
Badwe RA, Wang DY, Gregory WM, et al. Serum progesterone at the time of surgery and survival in women with premenopausal operable breast cancer. Eur J Cancer. 1994;30A(4):445–448.
First pregnancy characteristics and subsequent breast cancer risk among young women
Innes KE, Byers TE. First pregnancy characteristics and subsequent breast cancer risk among young women. Int J Cancer. 2004;112(2):306–311.
Estrogen receptor beta inhibits human breast cancer cell proliferation and tumor formation by causing a G2 cycle arrest
Paruthiyil S, Parma H, Kerekatte V, Cunha GR, Firestone GL, Leitman DC. Estrogen receptor beta inhibits human breast cancer cell proliferation and tumor formation by causing a G2 cycle arrest. Cancer Res. 2004;64(1):423–428.
Differential ligand activation of estrogen receptors ERalpha and ERbeta at AP1 sties
Paech K, Webb P, Kuiper GG, et al. Differential ligand activation of estrogen receptors ERalpha and ERbeta at AP1 sties. Science. 1997;277(5331):1508–1510.
Mechanisms of estrogen action
Nilsson S, Mäkelä S, Treuter E, et al. Mechanisms of estrogen action. Physiol Rev.2001;81(4):1535–1565.
Estrogen receptor beta acts a dominant regulator of estrogen signaling
Pettersson K, Delaunay F, Gustafsson JA. Estrogen receptor beta acts a dominant regulator of estrogen signaling. Oncogene. 2000;19(43):4970– 4978.
Quantitative structure activity relationship of various endogenous estrogen metabolites for human estrogen receptor alpha and beta subtypes: Insights into the structural determinants favoring a differential subtype binding
Zhu BT, Han GZ, Shim JY, Wen Y, Jiang XR. Quantitative structure activity relationship of various endogenous estrogen metabolites for human estrogen receptor alpha and beta subtypes: Insights into the structural determinants favoring a differential subtype binding. Endocrinology. 2006;147(9):4132–4150.
Pathophysiologic considerations in the treatment of menopausal patients with oestrogens; the role of oestriol in the prevention of mammary carcinoma
Lemon HM. Pathophysiologic considerations in the treatment of menopausal patients with oestrogens; the role of oestriol in the prevention of mammary carcinoma. Acta Endocrinol Suppl (Copenh). 1980;233:17–27.
Inhibition of radiogenic mammary carcinoma in rats by estriol or tamoxifen
Lemon HM, Kumar PF, Peterson C, Rodriguez-Sierra JF, Abbo KM. Inhibition of radiogenic mammary carcinoma in rats by estriol or tamoxifen. Cancer. 1989;63(9):1685–1692.
Estriol prevention of mammary carcinoma induced by 7,12- dimethylbenzanthracene and procarbazine
Lemon HM. Estriol prevention of mammary carcinoma induced by 7,12- dimethylbenzanthracene and procarbazine. Cancer Res. 1975;35(5):1341– 1353.
Oestrogen profiles of Asian and North American women
MacMahon B, Cole P, Brown JB, et al. Oestrogen profiles of Asian and North American women. Lancet. 1971;2(7730):900–902.
Differential response of estrogen receptor alpha and receptor beta to partial estrogen agonists/antagonists
Barkhem T, Carlsson B, Nilsson Y, Enmark E, Gustafsson J, Nilsson S. Differential response of estrogen receptor alpha and receptor beta to partial estrogen agonists/antagonists. Mol Pharmacol. 1998;54(1):105–112.
The major metabolite of equilin, 4- hyroxyequilin, autoxidizes to an oquinone with isomerizes to the potent cytotoxin 4-hydroyequilenin-o-quinone
Zhang F, Chen Y, Pisha E, et al. The major metabolite of equilin, 4- hyroxyequilin, autoxidizes to an oquinone with isomerizes to the potent cytotoxin 4-hydroyequilenin-o-quinone. Chem Res Toxicol. 1999;12(2):204–213.
A metabolite of equine estrogens, 4- hydroxyequilenin, induces DNA damage and apop tosis in breast cancer cell lines
Chen Y, Liu X, Pisha E, et al. A metabolite of equine estrogens, 4- hydroxyequilenin, induces DNA damage and apop tosis in breast cancer cell lines. Chem Res Toxicol. 2000;13(5):342–350.
Equineestrogen metabolite 4-hydroxyequilenin induces DNA damage in the rat mammary tissues: formation of single-strand breaks, apurinic sites, stable adducts, and oxidized bases
Zhang F, Swanson SM, van Breemen RB, et al. Equineestrogen metabolite 4-hydroxyequilenin induces DNA damage in the rat mammary tissues: formation of single-strand breaks, apurinic sites, stable adducts, and oxidized bases. Chem Res Toxicol. 2001;14(12):1654–1659.
Oestrogen fractions during early reproductive life in the aetiology of breast cancer
Cole P, MacMahon B. Oestrogen fractions during early reproductive life in the aetiology of breast cancer. Lancet. 1969;1(7595):604–606.
Molecular and kinetic basis for the mixed
Melamed M, Castaño E, Notides AC, Sasson S. Molecular and kinetic basis for the mixed
Molecular and kinetic basis for the mixed agonist/antagonist activity of estriol
agonist/antagonist activity of estriol. Mol Endocrinol. 1997;11(12):1868–1878.
Differentiation of the mammary gland and susceptibility to carcinogenesis
Russo J, Tay LK, Russo IH. Differentiation of the mammary gland and susceptibility to carcinogenesis. Breast Cancer Res Treat. 1982;2(1):5–73.
Pregnancy related protection against breast cancer depends on length of gestation
Vatten LJ, Romundstad PR, Trichopoulos D, Skjærven R. Pregnancy related protection against breast cancer depends on length of gestation. Br J Cancer. 2002;87(3):289–290.
Do urinary estrogen metabolites reflect the differences in breast cancer risk between Singapore Chinese and United States African-American and white women?
Ursin G, Wilson M, Henderson BE, et al. Do urinary estrogen metabolites reflect the differences in breast cancer risk between Singapore Chinese and United States African-American and white women? Cancer Res. 2001;61(8):3326–3329.
Genetic predisposition to carcinoma of the breast: multiple human genotypes for estrogen 16 alpha hydroxylase activity in Caucasians
Lemon HM. Genetic predisposition to carcinoma of the breast: multiple human genotypes for estrogen 16 alpha hydroxylase activity in Caucasians. J Surg Oncol. 1972;4(3):255–273.
Effects of estrone, estradiol, and estriol on hormone-responsive human breast cancer in long-term tissue culture
Lippman M, Monaco ME, Bolan G. Effects of estrone, estradiol, and estriol on hormone-responsive human breast cancer in long-term tissue culture. Cancer Res. 1977;37(6):1901–1907.
Reduced estriol excretion in patients with breast cancer prior to endocrine therapy
Lemon HM, Wotiz HH, Parsons L, Mozden PJ. Reduced estriol excretion in patients with breast cancer prior to endocrine therapy. JAMA. 1966;196(13):1128–136.
Ovarian steroid protection against coronary artery hyperreactivity in rhesus monkeys
Minshall RD, Stanczyk FZ, Miyagawa K, et al. Ovarian steroid protection against coronary artery hyperreactivity in rhesus monkeys. J Clin Endocrinol Metab. 1998;83(2):649–659.
Medroxyprogesterone Acetate and Dihydrotestosterone Induce Coronary Hyperreactivity in Intact Male Rhesus Monkeys
Mishra RG, Hermsmeyer RK, Miyagawas K, et al. Medroxyprogesterone acetate and
Medroxyprogesterone interferes with ovarian steroid protection against coronary vasospasm
Miyagawa K, Roöch J, Stanczyk F, Hermsmeyer K. Medroxyprogesterone interferes with ovarian steroid protection against coronary vasospasm. Nat Med. 1997;3(3):324–327.
Medroxyprogesterone acetate antagonizes inhibitory effects of conjugated equine estrogens on coronary artery atherosclerosis
Adams MR, Register TC, Golden DL, Wagner JD, Williams J. Medroxyprogesterone acetate antagonizes inhibitory effects of conjugated equine estrogens on coronary artery atherosclerosis. Arterioscler Thromb Vasc Biol. 1997;17(1):217–221.
Effects of estrogen or estrogen/progestin regimens on heart disease risk factors in postmenopausal women
Effects of estrogen or estrogen/progestin regimens on heart disease risk factors in postmenopausal women. The Postmenopausal Estrogen/Progestin Interventions (PEPI) Trial. The Writing Group for the PEPI Trial. JAMA. 1995;273(3):199–208.
L-norgestrel and progesterone have different influences on plasma lipoproteins
Fåhraeus L, Larsson-Cohn U, Wallentin L. L-norgestrel and progesterone have different influences on plasma lipoproteins. Eur J Clin Invest. 1983;13(6):447–453.
Oral progesterone and estrogen/progestogen therapy. Effects of natural and synthetic hormones on subfractions of HDL cholesterol and liver proteins
Ottosson UB. Oral progesterone and estrogen/progestogen therapy. Effects of natural and synthetic hormones on subfractions of HDL cholesterol and liver proteins. Acta Obstet Gynecol Scand Suppl. 1984;127:1–37.
Effects of different progestogens on lipoproteins during
Hirvonen E, Malkonen M, Manninen V. Effects of different progestogens on lipoproteins during
Estrogen plus progestin and risk of venous thrombosis
Cushman M, Kuller LH, Prentice R, et al. Estrogen plus progestin and risk of venous thrombosis. JAMA. 20, 2004;292(13):1573–1580.
Hormone therapy and venous thromboembolism among postmenopausal women: impact of the route of estrogen administration and progestogens: the ESTHER study
Canonico M, Oger E, Plu-Bureau G, et al. Hormone therapy and venous thromboembolism among postmenopausal women: impact of the route of estrogen administration and progestogens: the ESTHER study. Circulation. 2007;115(7):840–845.
Natural progesterone, but not medroxyprogesterone acetate, enhances the beneficial effect of estrogen on exercise-induced myocardial ischemia in postmenopausal women
Rosano GM, Webb CM, Chierchia S, et al. Natural progesterone, but not medroxyprogesterone acetate, enhances the beneficial effect of estrogen on exercise-induced myocardial ischemia in postmenopausal women. J Am Coll Cardiol. 2000;36(7):2154–2159.
Effects of conjugated equine estrogen with and without three different progestogens on lipoproteins, high-density lipoprotein subfractions, and apolipoprotein A-1. Obstet Gynecol
Miller VT, Muesing RA, LaRosa JC, Stoy DB, Phillips EA, Stillman RJ. Effects of conjugated equine estrogen with and without three different progestogens on lipoproteins, high-density lipoprotein subfractions, and apolipoprotein A-1. Obstet Gynecol. 1991;77(2):235–240.
Progesterone, but not medroxyprogesterone, inhibits vascular cell adhesion molecule-1 expression in human vascular endothelial cells
Otsuki M, Saito H, Xu X, et al. Progesterone, but not medroxyprogesterone, inhibits vascular cell adhesion molecule-1 expression in human vascular endothelial cells. Arterioscler Thromb Vasc Biol. 2001;21(2):243–248.
Insulin resistance, secretion, and elimination in postmenopausal women receiving oral or transdermal hormone replacement therapy
Godsland IF, Gangar K, Walton C, et al. Insulin resistance, secretion, and elimination in postmenopausal women receiving oral or transdermal hormone replacement therapy. Metabolism.1993;42(7):846–853.
Thrombotic stroke in an otherwise healthy middle aged female related to the use of continuous-combined conjugated equine estrogens and medroxyprogesterone acetate
Feeman WE Jr. Thrombotic stroke in an otherwise healthy middle aged female related to the use of continuous-combined conjugated equine estrogens and medroxyprogesterone acetate. J Gend Specif Med. 2000;3(8):62–64.
Medroxyprogesterone acetate inhibits the cardioprotective effect of estrogen in experimental ischemia- reperfusion injury
Jeanes HL, Wanikiat P, Sharif I, Gray GA. Medroxyprogesterone acetate inhibits the cardioprotective effect of estrogen in experimental ischemia- reperfusion injury. Menopause. 2006;13(1):80–86.
Long-term effects of percutaneous estrogens and oral progesterone on serum lipoproteins in postmenopausal women
Jensen J, Riis BJ, Strøm V, Nilas L, Christiansen C. Long-term effects of percutaneous estrogens and oral progesterone on serum lipoproteins in postmenopausal women. Am J Obstet Gynecol. 1987;156(1):66–71.
Low- dose progesterone therapy in oestrogenised postmenopausal women: effects on plasma lipids, lipoproteins and liver function parameters
Bolaji II, Grimes H, Mortimer G, Tallon DF, Fottrell PF, O’Dwyer EM. Low- dose progesterone therapy in oestrogenised postmenopausal women: effects on plasma lipids, lipoproteins and liver function parameters. Eur J Obstet Gynecol Reprod Biol. 1993;48(1):61–68.
Estrogen and progesterone inhibit vascular smooth muscle proliferation
Morey AK, Pedram A, Razandi M, et al. Estrogen and progesterone inhibit vascular smooth muscle proliferation. Endocrinology. 1997;138(8):3330– 3339.
Effects of oral and transdermal estrogen/progesterone regimens on blood coagulation and fibrinolysis in postmenopausal women
Scarabin PY, Alhenc-Gelas M, Plu-Bureau G, Taisne P, Agher R, Aiach M. Effects of oral and transdermal estrogen/progesterone regimens on blood coagulation and fibrinolysis in postmenopausal women. A randomized controlled trial. Arterioscler Thromb Vasc Biol. 1997;17(11):3071–3078.
Transdermal estradiol does not impair hemostatic biomarkers in postmenopausal women
Martinez C, Basurto L, Zarate A, Saucedo R, Gaminio E, Collazo J. Transdermal estradiol does not impair hemostatic biomarkers in postmenopausal women. Maturitas. 2005;50(1):39–43.
Venous thromboembolism, myocardial infarction, and stroke among transdermal contraceptive system users
Cole JA, Norman H, Doherty M, Walker AM. Venous thromboembolism, myocardial infarction, and stroke among transdermal contraceptive system users. Obstet Gynecol. 2007;109(2 pt 1):339–346.
Natural progesterone and antihypertensive action
Rylance PB, Brincat M, Lafferty K, et al. Natural progesterone and antihypertensive action. Bri Med J. 1985(6461);290:13–14.
Estriol in the management of the menopause
Tzingounis VA, Aksu MF, Greenblatt RB. Estriol in the management of the menopause. JAMA.
Efficacy and safety of estriol replacement therapy for climacteric women
Yang TS, Tsan SH, Chang SP, Ng HT. Efficacy and safety of estriol replacement therapy for climacteric women. Chin Med J (Taipei). 1995;55:386–391.
Treatment of climacteric complaints with oestriol
Perovi D, Kopajtic B, Stankovi T. Treatment of climacteric complaints with oestriol. Arzneimittel-Forschung. 1975;25(6):962–964.
The effect of estriol on the cytology of urethra and vagina in postmenopausal women with genito-urinary symptoms
van der Linden MC, Gerretsen G, Brandhorst MS, Ooms EC, Kremer CM, Doesburg WH. The effect of estriol on the cytology of urethra and vagina in postmenopausal women with genito-urinary symptoms. Eur J Obstet Gynecol Reprod Biol. 1993;51(1):29–33.
Oestriol in the treatment of postmenopausal urgency: a multicentre study
Cardoza L, Rekers H, Tapp A, et al. Oestriol in the treatment of postmenopausal urgency: a multicentre study. Maturitas. 1993;18(1):47–53.
Progesterone and bone: actions promoting bone health in women
Seifert-Klauss V, Prior JC. Progesterone and bone: actions promoting bone health in women. J Osteoporos. 2010 Oct 31;2010:845180.
Hormone replacement therapy and incidence of Alzheimer disease in older women: the Cache County Study
Zandi PP, Carlson MC, Plassman BL, Welsh-Bohmer KA, Mayer LS, Steffens DC, Breitner JC; Cache County Memory Study Investigators. Hormone replacement therapy and incidence of Alzheimer disease in older women: the Cache County Study. JAMA. 2002 Nov 6;288(17):2123-9.
Estrogen replacement therapy and risk of Alzheimer disease
Paganini-Hill A, Henderson VW. Estrogen replacement therapy and risk of Alzheimer disease. Arch Intern Med. 1996 Oct 28;156(19):2213-7.
Comparative measurements of serum Estriol, Estradiol, and Estrone in non-pregnant, premenopausal women: A preliminary investigation
Wright JV, Schliesman B, Robinson L. Comparative measurements of serum Estriol, Estradiol, and Estrone in non-pregnant, premenopausal women: A preliminary investigation. Altern Med Rev 1999;4(4):266-270.
The bioidentical hormone debate: are bioidentical hormones (Estradiol, Estriol, and Progesterone) safer or more efficacious than commonly used synthetic versions in Hormone Replacement Therapy?
Holtorf K. The bioidentical hormone debate: are bioidentical hormones (Estradiol, Estriol, and Progesterone) safer or more efficacious than commonly used synthetic versions in Hormone Replacement Therapy? Postgrad Med 2009;121(1): 73-85.
Estrogen receptors alpha (ERalpha) and beta (ERbeta) differentially regulate proliferation and apoptosis of the normal murine mammary epithelial cell line HC11
Helguero LA, Faulds MH, Gustafsson JA, Haldosén LA. Estrogen receptors alpha (ERalpha) and beta (ERbeta) differentially regulate proliferation and apoptosis of the normal murine mammary epithelial cell line HC11. Oncogene. 2005;24(44):6605–6616.
Loss of Erbeta expression as a common step in estrogen-dependent tumor progression
Bardin A, Boulle N, Lazennec G, Vignon F, Pujol P. Loss of Erbeta expression as a common step in estrogen-dependent tumor progression. Endocr Relat Cancer. 2004;11(3):537–551.
Increased risk of endometrial carcinoma among users of conjugated estrogens
Ziel HK, Finkle WD. Increased risk of endometrial carcinoma among users of conjugated estrogens. N Engl J Med. 1975 Dec 4;293(23):1167-70.
